cisapride has been researched along with Leukemia, Myeloid, Acute in 1 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Compound 27e, an orally bioavailable dual FLT3 and Aurora kinase inhibitor, was selected as a preclinical development candidate for the treatment of human malignancies, in particular AML, in adults and children." | 1.38 | Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. ( Atrash, B; Avery, S; Bavetsias, V; Bayliss, R; Blagg, J; Box, G; Brown, N; Bush, K; Crumpler, S; de Haven Brandon, A; Eccles, SA; Faisal, A; Henley, A; Kosmopoulou, M; Linardopoulos, S; Moore, AS; Raynaud, FI; Sheldrake, PW; Sun, C; Valenti, M; Workman, P, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bavetsias, V | 1 |
| Crumpler, S | 1 |
| Sun, C | 1 |
| Avery, S | 1 |
| Atrash, B | 1 |
| Faisal, A | 1 |
| Moore, AS | 1 |
| Kosmopoulou, M | 1 |
| Brown, N | 1 |
| Sheldrake, PW | 1 |
| Bush, K | 1 |
| Henley, A | 1 |
| Box, G | 1 |
| Valenti, M | 1 |
| de Haven Brandon, A | 1 |
| Raynaud, FI | 1 |
| Workman, P | 1 |
| Eccles, SA | 1 |
| Bayliss, R | 1 |
| Linardopoulos, S | 1 |
| Blagg, J | 1 |
1 other study available for cisapride and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Aurora Kinas | 2012 |